Inxight Drugs

U.S. Department of Health & Human Services Divider Arrow

National Institutes of Health Divider Arrow

NCATS

Return Home Inxight Drugs

Home
Browse Drugs
Search
- Structure Search
- Sequence Search
Downloads
About

Show Filters

Hide Filters

Development Status

US Approved Rx

13

Other

1

Possibly Marketed Outside US

1

All Match

Any Match

Exclude Selected

Exclude Selected

Primary Target

Carnitine O-acetyltransferase

13

Carnitine O-palmitoyltransferase 1, liver isoform

13

Carnitine O-palmitoyltransferase 1, muscle isoform

13

Carnitine O-palmitoyltransferase 2, mitochondrial

13

Mitochondrial carnitine/acylcarnitine carrier protein

13

All Match

Any Match

Exclude Selected

Exclude Selected

Highest Phase

Approved

13

All Match

Any Match

Exclude Selected

Exclude Selected

Approval Year

1985

13

2012

1

Unknown

1

All Match

Any Match

Exclude Selected

Exclude Selected

Condition

Congestive heart failure

13

Peripheral arterial occlusive disorders

13

Systemic primary carnitine deficiency

13

Ulcerative colitis

13

Diabetic nephropathy

1

All Match

Any Match

Exclude Selected

Exclude Selected

Treatment Modality

Primary

13

Diagnostic

1

All Match

Any Match

Exclude Selected

Exclude Selected

CNS Activity

CNS Penetrant

13

All Match

Any Match

Exclude Selected

Exclude Selected

Originator

Sigma-Tau

13

Scheele, C.W.

1

All Match

Any Match

Exclude Selected

Exclude Selected

Substance Class

Chemical

15

All Match

Any Match

Exclude Selected

Exclude Selected

Code System

FDA UNII

15

PUBCHEM

15

CAS

14

EPA CompTox

10

SMS_ID

10

All Match

Any Match

Exclude Selected

Exclude Selected

ATC Level 1

ALIMENTARY TRACT AND METABOLISM

1

NERVOUS SYSTEM

1

All Match

Any Match

Exclude Selected

Exclude Selected

ATC Level 2

OTHER ALIMENTARY TRACT AND METABOLISM PRODUCTS

1

PSYCHOANALEPTICS

1

All Match

Any Match

Exclude Selected

Exclude Selected

ATC Level 3

OTHER ALIMENTARY TRACT AND METABOLISM PRODUCTS

1

PSYCHOSTIMULANTS, AGENTS USED FOR ADHD AND NOOTROPICS

1

All Match

Any Match

Exclude Selected

Exclude Selected

ATC Level 4

Amino acids and derivatives

1

Other psychostimulants and nootropics

1

All Match

Any Match

Exclude Selected

Exclude Selected

Substance Form

Salts, Hydrates, Esters, etc.

12

Principal Form

3

All Match

Any Match

Exclude Selected

Exclude Selected

Showing 1 - 10 of 15 results

First page disabled
Previous page disabled
1
Next page
Next page

LEVOCARNITINE

0G389FZZ9M

Export Data
Search for Structure

Status:

US Approved Rx (1985)

First approved in 1985

Class (Stereo):

CHEMICAL (ABSOLUTE)

Targets:

Carnitine O-palmitoyltransferase 2, mitochondrial

Mitochondrial carnitine/acylcarnitine carrier protein

Carnitine O-acetyltransferase

Carnitine O-palmitoyltransferase 1, liver isoform

Oxidative phosphorylation

Carnitine O-palmitoyltransferase 1, muscle isoform

Oxidative Stress

Conditions:

Systemic primary carnitine deficiency

Ulcerative colitis

Peripheral arterial occlusive disorders

Congestive heart failure

Levocarnitine propionate or Propionyl L-carnitine (PLC) is the propionyl ester of L-carnitine. Propionyl-L-carnitine stimulates energy production in ischaemic muscles by increasing citric acid cycle flux and stimulating pyruvate dehydrogenase activit...

y. The free radical scavenging activity of the drug may also be beneficial. Propionyl-L-carnitine improves coagulative fibrinolytic homeostasis in vasal endothelium and positively affects blood viscosity. It exhibits a high affinity for the muscle enzyme, carnitine acyl transferase, and as such readily converts into propionyl-CoA and free carnitine. Most studies of the therapeutic use of PLC are focused on the prevention and treatment of ischemic heart disease, congestive heart failure, hypertrophic heart disease, and peripheral arterial disease. PLC is marketed under the trade name Dromos®. It is indicated for patients with peripheral arterial occlusive disorders and for exercise intolerance enhancement in patients with chronic congestive heart failure. Dromos is marketed in Italy.

GALACTARIC ACID

E149J5OTIF

Export Data
Search for Structure

Status:

Other

Class (Stereo):

CHEMICAL (ACHIRAL)

Conditions:

Diabetic nephropathy

Galactaric acid (also known as Mucic acid) is a naturally occurring compound found in fruits, sugar beet and blood. Some basics studies revealed that the acid can be used as a biomarker for diabetic nephropathy diagnosis.

ETHYL ACETOACETATE

IZP61H3TB1

Export Data
Search for Structure

Status:

Possibly Marketed Outside US

First approved in 2012

Class (Stereo):

CHEMICAL (ACHIRAL)

LEVOCARNITINE FUMARATE

8Q37GK439O

Export Data
Search for Structure

Status:

US Approved Rx (1985)

First approved in 1985

Class (Stereo):

CHEMICAL (ABSOLUTE)

Targets:

Carnitine O-palmitoyltransferase 2, mitochondrial

Mitochondrial carnitine/acylcarnitine carrier protein

Carnitine O-acetyltransferase

Carnitine O-palmitoyltransferase 1, liver isoform

Oxidative phosphorylation

Carnitine O-palmitoyltransferase 1, muscle isoform

Oxidative Stress

Conditions:

Systemic primary carnitine deficiency

Ulcerative colitis

Peripheral arterial occlusive disorders

Congestive heart failure

Levocarnitine propionate or Propionyl L-carnitine (PLC) is the propionyl ester of L-carnitine. Propionyl-L-carnitine stimulates energy production in ischaemic muscles by increasing citric acid cycle flux and stimulating pyruvate dehydrogenase activit...

y. The free radical scavenging activity of the drug may also be beneficial. Propionyl-L-carnitine improves coagulative fibrinolytic homeostasis in vasal endothelium and positively affects blood viscosity. It exhibits a high affinity for the muscle enzyme, carnitine acyl transferase, and as such readily converts into propionyl-CoA and free carnitine. Most studies of the therapeutic use of PLC are focused on the prevention and treatment of ischemic heart disease, congestive heart failure, hypertrophic heart disease, and peripheral arterial disease. PLC is marketed under the trade name Dromos®. It is indicated for patients with peripheral arterial occlusive disorders and for exercise intolerance enhancement in patients with chronic congestive heart failure. Dromos is marketed in Italy.

ACETYL-L-CARNITINE ARGINATE DIHYDROCHLORIDE

DDL9STT4CE

Export Data
Search for Structure

Status:

US Approved Rx (1985)

First approved in 1985

Class (Stereo):

CHEMICAL (ABSOLUTE)

Targets:

Carnitine O-palmitoyltransferase 2, mitochondrial

Mitochondrial carnitine/acylcarnitine carrier protein

Carnitine O-acetyltransferase

Carnitine O-palmitoyltransferase 1, liver isoform

Oxidative phosphorylation

Carnitine O-palmitoyltransferase 1, muscle isoform

Oxidative Stress

Conditions:

Systemic primary carnitine deficiency

Ulcerative colitis

Peripheral arterial occlusive disorders

Congestive heart failure

Levocarnitine propionate or Propionyl L-carnitine (PLC) is the propionyl ester of L-carnitine. Propionyl-L-carnitine stimulates energy production in ischaemic muscles by increasing citric acid cycle flux and stimulating pyruvate dehydrogenase activit...

y. The free radical scavenging activity of the drug may also be beneficial. Propionyl-L-carnitine improves coagulative fibrinolytic homeostasis in vasal endothelium and positively affects blood viscosity. It exhibits a high affinity for the muscle enzyme, carnitine acyl transferase, and as such readily converts into propionyl-CoA and free carnitine. Most studies of the therapeutic use of PLC are focused on the prevention and treatment of ischemic heart disease, congestive heart failure, hypertrophic heart disease, and peripheral arterial disease. PLC is marketed under the trade name Dromos®. It is indicated for patients with peripheral arterial occlusive disorders and for exercise intolerance enhancement in patients with chronic congestive heart failure. Dromos is marketed in Italy.

GLYCINE PROPIONYL-L-CARNITINE HYDROCHLORIDE

LY38SJU4DG

Export Data
Search for Structure

Status:

US Approved Rx (1985)

First approved in 1985

Class (Stereo):

CHEMICAL (ABSOLUTE)

Targets:

Carnitine O-palmitoyltransferase 2, mitochondrial

Mitochondrial carnitine/acylcarnitine carrier protein

Carnitine O-acetyltransferase

Carnitine O-palmitoyltransferase 1, liver isoform

Oxidative phosphorylation

Carnitine O-palmitoyltransferase 1, muscle isoform

Oxidative Stress

Conditions:

Systemic primary carnitine deficiency

Ulcerative colitis

Peripheral arterial occlusive disorders

Congestive heart failure

Levocarnitine propionate or Propionyl L-carnitine (PLC) is the propionyl ester of L-carnitine. Propionyl-L-carnitine stimulates energy production in ischaemic muscles by increasing citric acid cycle flux and stimulating pyruvate dehydrogenase activit...

y. The free radical scavenging activity of the drug may also be beneficial. Propionyl-L-carnitine improves coagulative fibrinolytic homeostasis in vasal endothelium and positively affects blood viscosity. It exhibits a high affinity for the muscle enzyme, carnitine acyl transferase, and as such readily converts into propionyl-CoA and free carnitine. Most studies of the therapeutic use of PLC are focused on the prevention and treatment of ischemic heart disease, congestive heart failure, hypertrophic heart disease, and peripheral arterial disease. PLC is marketed under the trade name Dromos®. It is indicated for patients with peripheral arterial occlusive disorders and for exercise intolerance enhancement in patients with chronic congestive heart failure. Dromos is marketed in Italy.

GLYCINE PROPIONYL-L-CARNITINE

8KVN59D5FL

Export Data
Search for Structure

Status:

US Approved Rx (1985)

First approved in 1985

Class (Stereo):

CHEMICAL (ABSOLUTE)

Targets:

Carnitine O-palmitoyltransferase 2, mitochondrial

Mitochondrial carnitine/acylcarnitine carrier protein

Carnitine O-acetyltransferase

Carnitine O-palmitoyltransferase 1, liver isoform

Oxidative phosphorylation

Carnitine O-palmitoyltransferase 1, muscle isoform

Oxidative Stress

Conditions:

Systemic primary carnitine deficiency

Ulcerative colitis

Peripheral arterial occlusive disorders

Congestive heart failure

Levocarnitine propionate or Propionyl L-carnitine (PLC) is the propionyl ester of L-carnitine. Propionyl-L-carnitine stimulates energy production in ischaemic muscles by increasing citric acid cycle flux and stimulating pyruvate dehydrogenase activit...

y. The free radical scavenging activity of the drug may also be beneficial. Propionyl-L-carnitine improves coagulative fibrinolytic homeostasis in vasal endothelium and positively affects blood viscosity. It exhibits a high affinity for the muscle enzyme, carnitine acyl transferase, and as such readily converts into propionyl-CoA and free carnitine. Most studies of the therapeutic use of PLC are focused on the prevention and treatment of ischemic heart disease, congestive heart failure, hypertrophic heart disease, and peripheral arterial disease. PLC is marketed under the trade name Dromos®. It is indicated for patients with peripheral arterial occlusive disorders and for exercise intolerance enhancement in patients with chronic congestive heart failure. Dromos is marketed in Italy.

ACETYL-L-CARNITINE ARGINATE

PIY2W03CO6

Export Data
Search for Structure

Status:

US Approved Rx (1985)

First approved in 1985

Class (Stereo):

CHEMICAL (ABSOLUTE)

Targets:

Carnitine O-palmitoyltransferase 2, mitochondrial

Mitochondrial carnitine/acylcarnitine carrier protein

Carnitine O-acetyltransferase

Carnitine O-palmitoyltransferase 1, liver isoform

Oxidative phosphorylation

Carnitine O-palmitoyltransferase 1, muscle isoform

Oxidative Stress

Conditions:

Systemic primary carnitine deficiency

Ulcerative colitis

Peripheral arterial occlusive disorders

Congestive heart failure

Levocarnitine propionate or Propionyl L-carnitine (PLC) is the propionyl ester of L-carnitine. Propionyl-L-carnitine stimulates energy production in ischaemic muscles by increasing citric acid cycle flux and stimulating pyruvate dehydrogenase activit...

y. The free radical scavenging activity of the drug may also be beneficial. Propionyl-L-carnitine improves coagulative fibrinolytic homeostasis in vasal endothelium and positively affects blood viscosity. It exhibits a high affinity for the muscle enzyme, carnitine acyl transferase, and as such readily converts into propionyl-CoA and free carnitine. Most studies of the therapeutic use of PLC are focused on the prevention and treatment of ischemic heart disease, congestive heart failure, hypertrophic heart disease, and peripheral arterial disease. PLC is marketed under the trade name Dromos®. It is indicated for patients with peripheral arterial occlusive disorders and for exercise intolerance enhancement in patients with chronic congestive heart failure. Dromos is marketed in Italy.

LEVOCARNITINE MONOTARTRATE

4OCB0F120X

Export Data
Search for Structure

Status:

US Approved Rx (1985)

First approved in 1985

Class (Stereo):

CHEMICAL (ABSOLUTE)

Targets:

Carnitine O-palmitoyltransferase 2, mitochondrial

Mitochondrial carnitine/acylcarnitine carrier protein

Carnitine O-acetyltransferase

Carnitine O-palmitoyltransferase 1, liver isoform

Oxidative phosphorylation

Carnitine O-palmitoyltransferase 1, muscle isoform

Oxidative Stress

Conditions:

Systemic primary carnitine deficiency

Ulcerative colitis

Peripheral arterial occlusive disorders

Congestive heart failure

Levocarnitine propionate or Propionyl L-carnitine (PLC) is the propionyl ester of L-carnitine. Propionyl-L-carnitine stimulates energy production in ischaemic muscles by increasing citric acid cycle flux and stimulating pyruvate dehydrogenase activit...

y. The free radical scavenging activity of the drug may also be beneficial. Propionyl-L-carnitine improves coagulative fibrinolytic homeostasis in vasal endothelium and positively affects blood viscosity. It exhibits a high affinity for the muscle enzyme, carnitine acyl transferase, and as such readily converts into propionyl-CoA and free carnitine. Most studies of the therapeutic use of PLC are focused on the prevention and treatment of ischemic heart disease, congestive heart failure, hypertrophic heart disease, and peripheral arterial disease. PLC is marketed under the trade name Dromos®. It is indicated for patients with peripheral arterial occlusive disorders and for exercise intolerance enhancement in patients with chronic congestive heart failure. Dromos is marketed in Italy.

LEVOCARNITINE PROPIONATE

0HU2UI27HF

Export Data
Search for Structure

Status:

US Approved Rx (1985)

First approved in 1985

Class (Stereo):

CHEMICAL (ABSOLUTE)

Targets:

Carnitine O-palmitoyltransferase 2, mitochondrial

Mitochondrial carnitine/acylcarnitine carrier protein

Carnitine O-acetyltransferase

Carnitine O-palmitoyltransferase 1, liver isoform

Oxidative phosphorylation

Carnitine O-palmitoyltransferase 1, muscle isoform

Oxidative Stress

Conditions:

Systemic primary carnitine deficiency

Ulcerative colitis

Peripheral arterial occlusive disorders

Congestive heart failure

Levocarnitine propionate or Propionyl L-carnitine (PLC) is the propionyl ester of L-carnitine. Propionyl-L-carnitine stimulates energy production in ischaemic muscles by increasing citric acid cycle flux and stimulating pyruvate dehydrogenase activit...

y. The free radical scavenging activity of the drug may also be beneficial. Propionyl-L-carnitine improves coagulative fibrinolytic homeostasis in vasal endothelium and positively affects blood viscosity. It exhibits a high affinity for the muscle enzyme, carnitine acyl transferase, and as such readily converts into propionyl-CoA and free carnitine. Most studies of the therapeutic use of PLC are focused on the prevention and treatment of ischemic heart disease, congestive heart failure, hypertrophic heart disease, and peripheral arterial disease. PLC is marketed under the trade name Dromos®. It is indicated for patients with peripheral arterial occlusive disorders and for exercise intolerance enhancement in patients with chronic congestive heart failure. Dromos is marketed in Italy.

Showing 1 - 10 of 15 results

First page disabled
Previous page disabled
1
Next page
Next page

HHS VULNERABILITY DISCLOSURE

For language access assistance, contact the NCATS Public Information Officer

National Center for Advancing Translational Sciences (NCATS),
6701 Democracy Boulevard, Bethesda MD 20892-4874 • 301-594-8966


			version 1.1